People · Operator

BARRY M LITTLEJOHNS

Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology

1
Companies
1
Filings
$11.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Redwood Bioscience IncBiotechnologySeries A$11.9M$90.4M2014
Operator network

BARRY M LITTLEJOHNS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

MICHAEL BLANK · 5 companies · 1 sharedMICHAEL BLANKKAREN BOEZI · 3 companies · 1 sharedKAREN BOEZIJ GORDON FOULKES · 2 companies · 1 sharedJ GORDON FOULKESMichael M. Blank · 2 companies · 1 sharedMichael M. BlankBARRY LITTLEJOHNS · 1 companies · 1 sharedBARRY LITTLEJOHNSCarolyn Ian Bertozzi · 1 companies · 1 sharedCarolyn Ian Berto…DAVID GORDON RABUKA · 1 companies · 1 sharedDAVID GORDON RABU…David Ian Rabuka · 1 companies · 1 sharedDavid Ian RabukaEDWARD GORDON MCCRACKEN · 1 companies · 1 sharedEDWARD GORDON MCC…Karen Ian Boezi · 1 companies · 1 sharedKaren Ian BoeziKAREN M BOEZI · 1 companies · 1 sharedKAREN M BOEZIMichael Ian Blank · 1 companies · 1 sharedMichael Ian BlankPaul Ian Socolow · 1 companies · 1 sharedPaul Ian SocolowRedwood Bioscience Inc · $11.9M raisedRedwood Bioscience IncBARRY M LITTLEJOHNSBL
BARRY M LITTLEJOHNS Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside BARRY M LITTLEJOHNS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
MICHAEL BLANK15
KAREN BOEZI13
Michael M. Blank12
J GORDON FOULKES12
Carolyn Ian Bertozzi11
Paul Ian Socolow11
Michael Ian Blank11
Karen Ian Boezi11
EDWARD GORDON MCCRACKEN11
KAREN M BOEZI11
DAVID GORDON RABUKA11
BARRY LITTLEJOHNS11
David Ian Rabuka11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.